Heplisav-B; Janssen and more—News of Note by Angus Liu Wednesday, February 27, 2019 Here is some other vaccine news of note for the week.
Themis’ chikungunya vaccine nabs fast FDA review by Angus Liu Tuesday, February 26, 2019 Themis' win comes after the FDA granted the same designation to chikungunya candidates from PaxVax and Valneva.
Bavarian Nordic, vaccine hesitancy and more—News of Note by Eric Sagonowsky Wednesday, January 23, 2019 Here is some other vaccine news of note for the week.
Valneva looking to buy overlooked vaccines from Big Pharma: CEO by Eric Sagonowsky Wednesday, January 16, 2019 While Valneva already markets two vaccines, the company is open to building its commercial business through small acquisitions, its CEO said.
Emergent's new CEO, Valneva and more—News of Note by Angus Liu Wednesday, January 9, 2019 Here is some other vaccine news of note for the week.
Valneva scores quick FDA review for chikungunya vaccine by Eric Sagonowsky Wednesday, January 2, 2019 The FDA fast-tracked Valneva's shot against chikungunya, a disease with no approved vaccines.
Only active Lyme disease vaccine program moves to phase 2 by Angus Liu Wednesday, December 19, 2018 Since GSK pulled LYMErix in 2002, there's been no FDA-approved Lyme shot, and Valneva's VLA15 is the only active clinical program.
Emergent and Valneva's Zika vaccine clears phase 1 by Angus Liu Tuesday, November 20, 2018 A Zika vaccine candidate co-developed by Emergent BioSolutions and Valneva has turned up positive early-stage results.
Sanofi's Dengvaxia, HPV vaccine and more—News of Note by Eric Sagonowsky Wednesday, October 17, 2018 Here is some other vaccine news of note for the week.
TapImmune, IAVI and more—News of Note by Angus Liu Wednesday, October 10, 2018 Here is some other vaccine news of note for the week.
